Licensing · Announced 27 Aug 2021
Bio-Thera Solutions → Hikma Pharmaceuticals
Licensing deal between Bio-Thera Solutions (China) and Hikma Pharmaceuticals (United States), covering BAT2206 → STARJEMZA®, announced 27 Aug 2021. Value: Undisclosed.
Parties: Bio-Thera Solutions, Ltd (China) → Hikma Pharmaceuticals (United States)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- United States (Europe optional)
- Therapeutic area
- Oncology
- Asset
- BAT2206 → STARJEMZA® (ustekinumab-hmny), biosimilar referencing Stelara®
- Announced
- 27 Aug 2021
Our analysis
(1) Bio-Thera and Hikma have a multi-geography relationship ,
(2) Hikma is a two-continent commercialization partner for Chinese biosimilar developers (US and MENA). But the territory here is the US , so it strengthens the "Hikma = gateway for Chinese biologics"
Source: Hikma (FDA approval, May 2025)